• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by Edesa Biotech Inc.

    2/14/25 5:15:15 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EDSA alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM D

    Notice of Exempt Offering of Securities

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
       None
    Entity Type
    0001540159
    Stellar Biotechnologies, Inc.
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    Edesa Biotech, Inc.
    Jurisdiction of Incorporation/Organization
    BRITISH COLUMBIA, CANADA
    Year of Incorporation/Organization
    X Over Five Years Ago
       Within Last Five Years (Specify Year)
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    Edesa Biotech, Inc.
    Street Address 1 Street Address 2
    100 SPY COURT
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    MARKHAM ONTARIO, CANADA L3R 5H6 289-800-9600

    3. Related Persons

    Last Name First Name Middle Name
    MacDonald Sean
    Street Address 1 Street Address 2
    100 SPY COURT
    City State/Province/Country ZIP/PostalCode
    MARKHAM ONTARIO, CANADA L3R 5H6
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Nijhawan Pardeep
    Street Address 1 Street Address 2
    100 SPY COURT
    City State/Province/Country ZIP/PostalCode
    MARKHAM ONTARIO, CANADA L3R 5H6
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Oakes Frank
    Street Address 1 Street Address 2
    100 SPY COURT
    City State/Province/Country ZIP/PostalCode
    MARKHAM ONTARIO, CANADA L3R 5H6
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Sistilli Carlo
    Street Address 1 Street Address 2
    100 SPY COURT
    City State/Province/Country ZIP/PostalCode
    MARKHAM ONTARIO, CANADA L3R 5H6
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Brooks Michael
    Street Address 1 Street Address 2
    100 SPY COURT
    City State/Province/Country ZIP/PostalCode
    MARKHAM ONTARIO, CANADA L3R 5H6
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Lemieux Stephen
    Street Address 1 Street Address 2
    100 SPY COURT
    City State/Province/Country ZIP/PostalCode
    MARKHAM ONTARIO, CANADA L3R 5H6
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Chypyha Joan
    Street Address 1 Street Address 2
    100 SPY COURT
    City State/Province/Country ZIP/PostalCode
    MARKHAM ONTARIO, CANADA L3R 5H6
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Olson Charles
    Street Address 1 Street Address 2
    100 SPY COURT
    City State/Province/Country ZIP/PostalCode
    MARKHAM ONTARIO, CANADA L3R 5H6
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Marshall Patrick
    Street Address 1 Street Address 2
    100 SPY COURT
    City State/Province/Country ZIP/PostalCode
    MARKHAM ONTARIO, CANADA L3R 5H6
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Liu David
    Street Address 1 Street Address 2
    100 SPY COURT
    City State/Province/Country ZIP/PostalCode
    MARKHAM ONTARIO, CANADA L3R 5H6
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
    X Biotechnology
       Health Insurance
       Hospitals & Physicians
       Pharmaceuticals
       Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
      
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
       No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
    X Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2025-02-12    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
       Yes X No

    9. Type(s) of Securities Offered (select all that apply)

    X Equity    Pooled Investment Fund Interests
       Debt    Tenant-in-Common Securities
       Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
       Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security    Other (describe)

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
       Yes X No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number X None
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    Street Address 1 Street Address 2
    City State/Province/Country ZIP/Postal Code
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
       Foreign/non-US

    13. Offering and Sales Amounts

    Total Offering Amount $15,000,000 USD
    or    Indefinite
    Total Amount Sold $15,000,000 USD
    Total Remaining to be Sold $0 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    15

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $0 USD
       Estimate
    Finders' Fees $0 USD
       Estimate

    Clarification of Response (if Necessary):

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
    X Estimate

    Clarification of Response (if Necessary):

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    Edesa Biotech, Inc. /s/ Stephen Lemieux Stephen Lemieux CFO 2025-02-14

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $EDSA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EDSA

    DatePrice TargetRatingAnalyst
    12/20/2021$16.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $EDSA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference

      TORONTO, April 28, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that the company will participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference scheduled for May 5-6 2025 in Toronto, Ontario. Edesa management is scheduled to present on Monday, May 5 at 4:00pm ET. To meet with Edesa during the conference, please utilize the conference's online portal or contact the company directly at [email protected]. About Edesa Biotech Edesa Biotech, Inc. (NASDAQ:EDSA) is a clinical-stage biopharmaceutical company develop

      4/28/25 4:30:06 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edesa Biotech Announces Chief Financial Officer Transition

      TORONTO, April 04, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced the appointment of Peter J. Weiler as Chief Financial Officer, effective May 1, 2025. Mr. Weiler will succeed Stephen Lemieux, who will be stepping down from the role effective May 1, 2025, to pursue other professional opportunities. Mr. Weiler brings extensive experience in finance and corporate strategy within the biotechnology and pharmaceutical industries. Since August 2018, Mr. Weiler served as President of Exzell Pharma, Inc., a privately held, commercial-stage ph

      4/4/25 4:15:46 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edesa Biotech Reports Fiscal 1st Quarter 2025 Results

      TORONTO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three months ended December 31, 2024 and provided an update on its business. During the quarter, the company advanced its main asset, EB06, an anti-CXCL10 monoclonal antibody candidate being developed for the effective and durable treatment of vitiligo. Preparation for the manufacturing campaign is underway, with data anticipated to be submitted to regulators at the U.S. Food and Drug Administration (FDA) during the middle of 2025. The company in

      2/14/25 4:15:00 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EDSA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Nijhawan Pardeep was granted 6,392 shares, increasing direct ownership by 4% to 178,923 units (SEC Form 4)

      4 - Edesa Biotech, Inc. (0001540159) (Issuer)

      5/6/25 5:28:21 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Weiler Peter J.

      3 - Edesa Biotech, Inc. (0001540159) (Issuer)

      5/2/25 5:00:21 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Nijhawan Pardeep was granted 5,784 shares, increasing direct ownership by 3% to 172,531 units (SEC Form 4)

      4 - Edesa Biotech, Inc. (0001540159) (Issuer)

      4/3/25 5:25:30 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EDSA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Edesa Biotech Inc.

      SC 13D/A - Edesa Biotech, Inc. (0001540159) (Subject)

      11/1/24 8:50:52 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Edesa Biotech Inc.

      SC 13G - Edesa Biotech, Inc. (0001540159) (Subject)

      6/3/24 4:10:38 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Edesa Biotech Inc. (Amendment)

      SC 13G/A - Edesa Biotech, Inc. (0001540159) (Subject)

      1/29/24 4:29:02 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EDSA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Nijhawan Pardeep bought $20,000 worth of shares (5,000 units at $4.00) (SEC Form 4)

      4 - Edesa Biotech, Inc. (0001540159) (Issuer)

      3/25/24 7:00:59 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EDSA
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Edesa Biotech Inc.

      DEFA14A - Edesa Biotech, Inc. (0001540159) (Filer)

      4/4/25 4:23:38 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Edesa Biotech Inc.

      DEF 14A - Edesa Biotech, Inc. (0001540159) (Filer)

      4/4/25 4:22:10 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edesa Biotech Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - Edesa Biotech, Inc. (0001540159) (Filer)

      4/4/25 4:20:14 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EDSA
    Leadership Updates

    Live Leadership Updates

    See more
    • Edesa Biotech Announces Chief Financial Officer Transition

      TORONTO, April 04, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced the appointment of Peter J. Weiler as Chief Financial Officer, effective May 1, 2025. Mr. Weiler will succeed Stephen Lemieux, who will be stepping down from the role effective May 1, 2025, to pursue other professional opportunities. Mr. Weiler brings extensive experience in finance and corporate strategy within the biotechnology and pharmaceutical industries. Since August 2018, Mr. Weiler served as President of Exzell Pharma, Inc., a privately held, commercial-stage ph

      4/4/25 4:15:46 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edesa Biotech Appoints Biotech Deal Veteran to CFO Role

      TORONTO, ON / ACCESSWIRE / June 27, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the company's board of directors has appointed Stephen Lemieux, CPA to the role of Chief Financial Officer, effective July 15, 2023. He is a veteran of the healthcare and biopharmaceutical sectors, with more than 20 years of experience in financial planning and analysis, licensing and mergers & acquisitions."Stephen joins Edesa at an exciting time as we build on our regulatory and clinical achievements and set our sights on additional growth opportunities. He shares our disciplined, manage-like-owner

      6/27/23 8:15:00 AM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edesa Biotech Appoints Strategy Expert to Board of Directors

      TORONTO, ON / ACCESSWIRE / March 29, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the appointment of Jennifer M. Chao to the company's Board of Directors."Ms. Chao's appointment to our Board comes at an exciting time as we prepare for the most meaningful milestones yet in our clinical programs. Her extensive experience in the life science sector and capital markets will be a valuable resource to Edesa and its shareholders," said Par Nijhawan, MD, Chief Executive Officer of Edesa.Ms. Chao has more than 25 years of experience in the biotech and life sciences industries focused primarily

      3/29/22 9:00:00 AM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EDSA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. initiated coverage on Edesa Biotech with a new price target

      HC Wainwright & Co. initiated coverage of Edesa Biotech with a rating of Buy and set a new price target of $16.00

      12/20/21 6:08:21 AM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care